172033-73-7

Usage

Uses

Used in Organic Synthesis:
4-FLUORO-1-NAPHTHALDEHYDE is used as a synthetic building block for the creation of various organic compounds. Its fluorinated nature allows for specific reactivity patterns and can be employed in the development of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-FLUORO-1-NAPHTHALDEHYDE is used as a key intermediate in the synthesis of novel drug candidates. Its unique chemical properties enable the design of molecules with improved pharmacological profiles, such as enhanced potency, selectivity, and bioavailability.
Used in Chemical Research:
4-FLUORO-1-NAPHTHALDEHYDE is also utilized in academic and industrial research settings as a model compound for studying various chemical reactions and mechanisms. Its reactivity and structural features make it a valuable tool for understanding the behavior of fluorinated organic molecules and their potential applications in various fields.
Used in Material Science:
In the field of material science, 4-FLUORO-1-NAPHTHALDEHYDE can be used as a component in the development of advanced materials with specific properties, such as improved stability, reactivity, or selectivity. Its incorporation into polymers, coatings, or other materials can lead to enhanced performance characteristics for various applications.

Synthesis Reference(s)

The Journal of Organic Chemistry, 60, p. 6592, 1995 DOI: 10.1021/jo00125a055

InChI:InChI=1/C11H7FO/c12-11-6-5-8(7-13)9-3-1-2-4-10(9)11/h1-7H

Upstream product

• 4885-02-3 Dichloromethyl methyl ether 
• 321-38-0 1-Fluoronaphthalene 
• 42758-54-3 4-nitro-1-naphthaldehyde 
• 341-41-3 1-bromo-4-fluoronaphthalene 
• 68-12-2 N,N-dimethyl-formamide 
• 79996-88-6 (4-fluoronaphthalen-1-yl)methanol 

Downstream Products

• 172033-75-9 4-phenoxynaphthaldehyde 
• 172033-90-8 4-(phenylthio)-1-naphthaldehyde 
• 315-53-7 4-fluoro-1-hydroxynaphthalene 
• 925442-44-0 4-(2,4-dichlorophenoxy)-1-naphthaldehyde 
• 741693-83-4 4-Hydroxy-Duloxetine Glucuronide 
• 1266729-02-5 N-((4-fluoronaphthalen-1-yl)methyl)cyclopropanamine 
• 1234382-28-5 5-(3,5-dichloro-phenyl)-3-(4-fluoro-naphthalene-1-yl)-5-trifluoromethyl-4,5-dihydro-isoxazole 
• 1234382-23-0 3-(4-azido-naphthalen-1-yl)-5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazole 
• 1234381-37-3 1-{4-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-naphthalen-1-yl}-1H-[1,2,4]triazole 
• 1234382-07-0 N-(1-{4-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-naphthalen-1-yl}-1H-[1,2,3]triazol-4-ylmethyl)-isonicotinamide 
• 79996-88-6 (4-fluoronaphthalen-1-yl)methanol 
• 3094-25-5 1-(chloromethyl)-4-fluoronaphthalene 

Relevant academic research and scientific papers

Nickel-Catalyzed Amination of α-Aryl Methyl Ethers

α-Aryl amines are prevalent in pharmaceutically active compounds and natural products. Herein, we describe a Ni-catalyzed protocol for their synthesis from readily available α-aryl ethers. While α-aryl ethers have been used as electrophiles in Ni-catalyzed C-C bond formations, their use in C-heteroatom bond formation is much less prevalent. Preliminary mechanistic insight suggests that oxidative addition is facilitated by an anionic ligand and that reductive elimination is a reversible process.

OLIGOMER-ARYLOXY-SUBSTITUTED PROPANAMINE CONJUGATES

The invention relates to (among other things) oligomer- aryloxy-substituted propanamine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated aryloxy-substituted propanamine compounds.

RENIN INHIBITORS

Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency, wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R1 is hydrogen, C1-6 -alkyl or C3-6 -cycloalkyl, wherein said C1-6 -alkyl or C3-6 -cycloalkyl group can be independently substituted with 1-3 halogens; A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to another five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is a bond or -(C=O)-, -CH(OH)-, -CH2- or =CH-; U is a bond or -CH2-, or for the case when V is =CH-, U is -CH=; X is =CH-, =CF-, =C(OR3)-, or -C=O-; and Y is =CH-, =CF-, =N-, or for the case when X is -C=O-, Y is -N(R3)-.

Microwave-accelerated fluorodenitrations and nitrodehalogenations: expeditious routes to labeled PET ligands and fluoropharmaceuticals

Methods for the expeditious fluorination of arenes have been investigated, using readily available fluoride sources. An optimized procedure for microwave-accelerated fluorodenitration has been developed, giving good to excellent yields in less than 10 min, rendering it practical for use in the preparation of F18 labeled ligands for PET imaging. Application of the method in the synthesis of CNS agents is demonstrated, and a practical method for the preparation of substrates is also presented.

ISOXAZOLINES DERIVATIVES AND THEIR USE AS PESTICIDE

The invention relates to new pyrimidine compounds of formula (I) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful in the control of parasites, in particular ectoparasites, in and on warmblooded animals.

INHIBITORS OF CXCR2

The invention relates to compounds of the formula (I), in which R1, R2, X, A, B and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula (I) and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

NEW CXCR2 INHIBITORS

The invention relates to compounds of the formula (I), in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY

In part, the present invention is directed to antibacterial compounds of formula (I) wherein A is a bicyclic heteroaryl ring or a tricyclic ring and R2 is an heterocyclic residue; L is a bond, or L is alkyl, alkenyl or cycloalkyl.

Synthesis and biological activity of some known and putative duloxetine metabolites

Several putative phase I duloxetine metabolites, 4-hydroxy-, 5-hydroxy-, 6-hydroxy-, 5-hydroxy-6-methoxy-, 6-hydroxy-5-methoxy-, 5,6-dihydroxy-, and 4,6-dihydroxyduloxetine were synthesized, and their phase II metabolite as glucuronide or sulfate conjugates were also synthesized. Their in vitro binding activities were compared to that of parent compound duloxetine.